Novel nanoparticles for the delivery of recombinant hepatitis B vaccine
β Scribed by Dhruba J. Bharali; Vandana Pradhan; Galina Elkin; Wu Qi; Alan Hutson; Shaker A. Mousa; Yasmin Thanavala
- Book ID
- 103849479
- Publisher
- Elsevier Science
- Year
- 2008
- Tongue
- English
- Weight
- 354 KB
- Volume
- 4
- Category
- Article
- ISSN
- 1549-9634
No coin nor oath required. For personal study only.
β¦ Synopsis
We describe the use of methoxypolyethylene glycol-poly(lactide-co-glycolide) nanoparticles as a delivery system for recombinant hepatitis B surface antigen (HBsAg). Evaluation of the stability and release kinetics of nanoencapsulated HBsAg in vitro in serum revealed an initial burst effect and a subsequent slower release of the antigen. Importantly the antigenicity was not destroyed by the encapsulation process, because upon release it was able to react with an anti-HBs antibody. Bone marrow-derived dendritic cells showed efficient uptake of the nanoparticle vaccine as visualized by confocal imaging. To determine whether nano-encapsulated HBsAg was capable of eliciting an immune response in the absence of an adjuvant, mice were immunized with the nanoparticle vaccine or with nonencapsulated recombinant HBsAg. In mice immunized with the nanoparticle vaccine, anti-HBs antibodies were detected at significantly earlier time points than in mice immunized with the nonencapsulated recombinant HBsAg.
π SIMILAR VOLUMES
The objective of this work was to obtain a nanoparticle formulation that could be sterile filtered, lyophilized, and resuspended to the initial size with excipients appropriate for use as a vaccine formulation. Poly(lactide-co-glycolide) (PLG) polymers were used to create nanoparticles ranging in si
## Abstract Hepatitis B and its sequelae are a major public health problem. Vaccines have been available for almost 20 years; however the disease still remains a global problem. Many factors contribute to the failure to control hepatitis B, including the limited nature of the vaccination programs i
## Abstract ## Background Chitosan has been shown to possess useful properties such as nonβtoxicity, high biocompatibility and nonβantigenicity that offer advantages for vaccine delivery systems. In this study, we prepared novel chitosan derivative nanoparticles as DNA vaccine carriers and the pot